myricetin
common
dietari
flavonoid
report
possess
mani
differ
biolog
activ
antioxid
antiinflammatori
antivir
effect
studi
explor
antihsv
effect
mechan
myricetin
vitro
vivo
result
show
myricetin
possess
activ
low
toxic
superior
effect
acyclovir
myricetin
may
block
hsv
infect
direct
interact
viru
gd
protein
interfer
viru
adsorpt
membran
fusion
differ
nucleosid
analogu
acyclovir
myricetin
also
downregul
cellular
akt
signal
pathway
inhibit
hsv
infect
subsequ
replic
importantli
intraperiton
therapi
myricetin
markedli
improv
mice
surviv
reduc
viru
titer
lung
spinal
cord
therefor
natur
dietari
flavonoid
myricetin
potenti
develop
novel
antihsv
agent
target
viru
gd
protein
cellular
pathway
herp
simplex
viru
type
type
envelop
doubl
strand
dna
virus
belong
herpesvirida
fatahzadeh
schwartz
hsv
infect
caus
skin
lesion
gener
local
oral
nasal
ocular
level
infect
wherea
infect
commonli
occur
genitalskin
mucosa
site
liu
cohen
smith
robinson
approxim
adult
human
popul
worldwid
seraposit
carr
et
al
current
fda
approv
antivir
agent
herpesvirus
involv
mainli
nucleosid
analogu
acyclovir
acv
pencyclovir
mainli
inhibit
viral
genom
replic
despit
success
drug
resist
side
effect
remain
unresolv
issu
fight
hsv
infect
morfin
thouvenot
henc
develop
novel
antihsv
agent
activ
mechan
differ
nucleosid
analogu
high
import
myricetin
common
dietari
flavonoid
plant
sourc
veget
fruit
tea
antioxid
properti
ong
khoo
ross
kasum
like
flavonoid
myricetin
report
possess
mani
differ
biolog
activ
antimicrobi
antithrombot
neuroprotect
antiinflammatori
effect
cushni
lamb
daja
et
al
gupta
et
al
ong
khoo
santhakumar
et
al
semwal
et
al
tian
et
al
pasetto
et
al
report
myricetin
possess
activ
low
toxic
mainli
inhibit
activ
hiv
revers
transcriptas
pasetto
et
al
lyu
et
al
found
flavonoid
myricetin
quercetinin
show
moder
inhibitori
effect
vero
cell
lyu
et
al
yu
cowork
found
myricetin
scutellarein
potent
inhibit
sarscov
helicas
protein
vitro
affect
atpas
activ
suggest
myricetin
scultellarein
might
serv
sarscov
chemic
inhibitor
yu
et
al
thu
myricetin
potenti
develop
novel
antivir
agent
correl
antivir
applic
myricetin
underli
molecular
mechan
antihsv
effect
mechan
myricetin
investig
vitro
vivo
studi
result
show
myricetin
possess
activ
low
toxic
myricetin
may
block
hsv
http
receiv
octob
receiv
revis
form
decemb
accept
januari
infect
direct
interact
viru
gd
protein
interfer
viru
adsorpt
membran
fusion
moreov
intraperiton
therapi
myricetin
markedli
improv
mice
surviv
reduc
viru
titer
lung
spinal
cord
thu
myricetin
merit
investig
novel
antihsv
agent
futur
myricetin
puriti
purchas
topscienc
co
ltd
shanghai
china
acyclovir
purchas
sigma
aldrich
st
loui
mo
usa
vero
hela
cell
routin
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
excel
bio
china
penicillin
uml
streptomycin
co
strain
f
purchas
atcc
strain
obtain
wuhan
institut
virolog
chines
academi
scienc
antivir
activ
evalu
cpe
inhibit
assay
dai
et
al
briefli
vero
cell
plate
infect
multipl
infect
moi
treat
indic
concentr
myricetin
triplic
remov
viru
inoculum
h
incub
cell
fix
formaldehyd
min
room
temperatur
rt
remov
formaldehyd
cell
stain
wv
crystal
violet
min
plate
wash
dri
intens
crystal
violet
stain
well
measur
nm
concentr
requir
test
compound
reduc
cpe
hsv
ic
determin
pfuwel
preincub
without
myricetin
min
infect
virusmyricetin
mixtur
transfer
vero
cell
monolay
plate
incub
h
gentl
shake
everi
min
inoculum
remov
well
overlaid
ml
agar
overlay
media
contain
agaros
uml
penicillin
streptomycin
cell
incub
plaqu
size
adequ
cell
fix
paraformaldehyd
pfa
stain
crystal
violet
plaqu
count
vero
cell
infect
moi
four
differ
treatment
condit
pretreat
viru
myricetin
pretreat
hsv
ad
vero
cell
incub
h
adsorpt
viru
innuculum
contain
myricetin
remov
cell
overlaid
compoundfre
media
ii
pretreat
cell
vero
cell
pretreat
myricetin
hsv
infect
iii
adsorpt
vero
cell
infect
media
contain
myricetin
h
viru
innuculum
remov
compoundfre
media
ad
cell
iv
postadsorpt
remov
unabsorb
viru
myricetin
ad
cell
h
pi
viru
yield
determin
plaqu
assay
indirect
immunofluoresc
assay
perform
previous
describ
briefli
hsv
bind
assay
moi
adsorb
hela
cell
h
absenc
presenc
myricetin
wash
pb
entri
assay
moi
firstli
adsorb
hela
cell
h
wash
pb
myricetin
ad
cell
incub
h
cell
treat
proteinas
k
remov
adsorb
intern
viru
cell
wash
pb
fix
paraformaldehyd
min
cell
permeabil
use
v
v
triton
pb
min
incub
bsa
h
wash
cell
incub
consecut
antibodi
dilut
dylight
secondari
antibodi
cell
nucleu
stain
dapi
min
confoc
imag
imag
record
use
nikon
confoc
microscop
analys
imagej
nih
version
u
usa
total
rna
extract
hsv
infect
vero
cell
use
plu
kit
takara
japan
analys
use
one
step
sybr
primescript
rtpcr
kit
takara
japan
primer
pair
hsv
gd
cellular
mrna
list
follow
gd
mrna
monkey
mrna
realtim
rtpcr
perform
min
cycl
follow
melt
curv
analysi
accord
instrument
document
abi
prism
appli
biosystem
usa
reaction
perform
triplic
result
normal
rel
amount
hsv
gd
mrna
molecul
determin
use
compar
method
previous
describ
livak
schmittgen
dart
experi
identifi
target
myricetin
perform
previous
report
lomenick
et
al
briefli
moi
infect
vero
cell
lyse
cell
lysi
buffer
beyotim
nantong
china
treat
without
myricetin
h
room
temperatur
rt
follow
digest
pronas
reaction
buffer
mm
trishcl
ph
mm
nacl
mm
min
rt
digest
stop
directli
add
sdspage
load
buffer
inactiv
boil
protein
sampl
separ
sdspolyacrylamid
gel
analys
western
blot
antibodi
gd
gb
gc
ghgl
protein
cellular
hvem
actin
tubulin
protein
control
spr
assay
conduct
spr
biosensor
instrument
ge
ge
usa
gd
protein
biodragon
beij
china
firstli
immobil
onto
surfac
carboxymethyl
dextran
sensor
chip
via
amino
group
coupl
describ
previous
geng
et
al
assess
realtim
bind
myricetin
gd
protein
chip
myricetin
differ
concentr
dissolv
dmso
inject
sensor
chip
surfac
gd
immobil
within
min
follow
wash
pbst
buffer
sensor
chip
surfac
regener
wash
naoh
mm
bind
experi
carri
constant
flow
rate
pb
buffer
correct
nonspecif
bind
bulk
refract
index
chang
blank
channel
without
gd
use
run
simultan
experi
spr
evalu
softwar
use
calcul
kinet
paramet
chang
mass
due
bind
respons
record
w
li
et
al
antivir
research
reson
unit
ru
drug
treatment
cell
lysat
separ
sdspage
transfer
nitrocellulos
membran
block
trisbuff
salin
tb
contain
tween
vv
bsa
w
v
rt
h
membran
rins
incub
overnight
primari
antibodi
phosphoryl
nonphosphoryl
egfr
akt
antibodi
gapdh
antibodi
cell
signal
technolog
danver
usa
control
membran
wash
incub
aplabel
secondari
antibodi
dilut
rt
h
protein
band
visual
incub
develop
solut
pnitro
blue
tetrazolium
chlorid
nbt
phosphat
toluidin
bcip
rt
min
rel
densiti
protein
determin
use
imagej
nih
u
usa
cell
fusion
inhibit
assay
perform
describ
modif
du
et
al
monolay
vero
cell
grown
plate
infect
moi
h
remov
viru
inoculum
compound
free
media
ad
cell
incub
h
myricetin
ad
cell
incub
anoth
h
cell
fix
detect
hematoxylineosin
stain
inhibit
syncytium
format
examin
light
microscopi
influenc
myricetin
hsv
glycoprotein
express
h
post
infect
also
evalu
western
blot
molecular
dock
conduct
moe
moe
structur
myricetin
drawn
chembiodraw
convert
structur
moe
energi
minim
structur
protein
gd
download
rcsb
protein
data
bank
pdb
id
prior
dock
forc
field
eht
implicit
solvat
model
reaction
field
rfield
select
moedock
use
molecular
dock
simul
myricetin
gd
dock
workflow
follow
induc
fit
protocol
side
chain
receptor
pocket
allow
move
accord
ligand
conform
constraint
posit
weight
use
tether
side
chain
atom
origin
posit
ligand
dock
pose
rank
london
dg
score
first
forc
field
refin
carri
top
pose
follow
rescor
gbviwsa
dg
conform
lowest
free
energi
bind
select
best
probabl
bind
mode
molecular
graphic
gener
pymol
anim
experi
perform
accord
nation
institut
health
guid
care
use
laboratori
anim
approv
institut
anim
care
use
committe
ocean
univers
china
threeweekold
femal
balb
c
mice
averag
weight
g
purchas
beij
vital
river
laboratori
anim
technolog
co
ltd
beij
china
rais
pathogenfre
environ
humid
mice
randomli
divid
five
experiment
group
mice
mice
anaesthet
infect
via
intranas
rout
pfu
f
strain
pb
four
hour
inocul
mice
receiv
intraperiton
treatment
acyclovir
myricetin
placebo
treatment
repeat
daili
five
day
day
mice
weigh
monitor
sign
ill
day
suffer
sever
infect
lost
origin
bodi
weight
euthan
determin
viru
titer
organ
mice
euthan
lung
brain
spinal
cord
remov
homogen
clarifi
centrifug
day
inocul
sampl
assay
viru
titer
plaqu
assay
quantit
rtpcr
assay
histopatholog
analysi
also
perform
use
h
e
stain
lung
brain
sampl
collect
day
data
repres
least
three
independ
experi
data
present
mean
standard
deviat
sd
statist
signific
analys
use
graphpad
prism
softwar
use
oneway
anova
turkey
test
p
valu
consid
signific
myricetin
member
flavonoid
class
polyphenol
compound
antioxid
properti
structur
shown
fig
herein
antihsv
effect
mechan
myricetin
investig
vitro
cytotox
myricetin
vero
hela
cell
firstli
assess
mtt
assay
livak
schmittgen
result
show
myricetin
exhibit
signific
cytotox
concentr
fig
cc
cytotox
concentr
valu
myricetin
vero
hela
cell
respect
tabl
myricetin
assay
abil
inhibit
hsv
multipl
vitro
use
cpe
inhibit
assay
plaqu
assay
briefli
f
strain
strain
moi
pretreat
myricetin
h
infect
adsorpt
media
contain
myricetin
indic
concentr
ad
cell
h
pi
viral
titer
cultur
media
determin
plaqu
assay
cell
viabil
measur
cpe
inhibit
assay
shown
fig
myricetin
significantli
reduc
viru
titer
vero
cell
use
concentr
p
cpe
inhibit
assay
show
ic
valu
myricetin
respect
select
index
cc
ic
myricetin
respect
superior
acyclovir
acv
si
tabl
myricetin
also
inhibit
hsv
replic
hela
cell
si
tabl
addit
plaqu
reduct
assay
show
pretreat
hsv
myricetin
concentr
significantli
reduc
number
plaqu
infect
cell
fig
suggest
myricetin
may
abl
inactiv
viral
particl
directli
timeofaddit
assay
perform
determin
stage
myricetin
exert
inhibit
action
vitro
brief
myricetin
ad
vero
cell
four
differ
condit
pretreat
virus
pretreat
cell
viru
adsorpt
adsorpt
subsequ
antivir
activ
determin
plaqu
assay
shown
fig
pretreat
myricetin
h
infect
significantli
reduc
viru
titer
hsv
compar
nontreat
viru
control
group
p
suggest
myricetin
may
direct
w
li
et
al
antivir
research
interact
hsv
particl
treatment
myricetin
adsorpt
adsorpt
also
possess
obviou
inhibit
viru
multipl
p
fig
howev
pretreat
cell
significantli
reduc
viru
titer
vitro
fig
suggest
myricetin
may
interact
vero
cell
directli
moreov
indirect
immunofluoresc
assay
four
condit
pachota
et
al
indic
pretreat
viru
myricetin
infect
also
significantli
reduc
express
infect
cell
fig
concern
result
plaqu
assay
fig
thu
myricetin
may
interact
viru
particl
block
adsorpt
hsv
inhibit
step
viru
adsorpt
sinc
myricetin
may
abl
block
adsorpt
postadsorpt
process
hsv
explor
potenti
inhibit
myricetin
hsv
bind
entri
process
use
immunofluoresc
assay
briefli
hsv
bind
assay
moi
adsorb
hela
cell
h
absenc
presenc
myricetin
wash
pb
entri
assay
moi
firstli
adsorb
hela
cell
h
wash
pb
myricetin
ad
cell
incub
h
cell
treat
proteinas
k
remov
adsorb
intern
viru
immunofluoresc
assay
perform
determin
amount
hsv
virion
bind
enter
hela
cell
shown
fig
e
myricetin
treatment
adsorpt
significantli
decreas
fluoresc
protein
cell
surfac
compar
nontreat
viru
control
cell
suggest
myricetin
may
block
viru
adsorpt
process
hsv
moreov
h
pi
mani
fluoresc
spot
could
found
nucleu
area
white
arrow
indic
suggest
nucleocapsid
egress
late
endosom
deliv
nuclear
peripheri
hela
cell
fig
howev
myricetin
treatment
entri
process
dramat
reduc
fluoresc
cytoplasm
littl
fluoresc
could
observ
cell
nucleu
suggest
myricetin
may
also
abl
block
hsv
entri
process
hela
cell
fig
thu
myricetin
may
possibl
block
hsv
infect
mainli
interf
hsv
bind
entri
process
sinc
myricetin
may
block
hsv
bind
entri
process
ask
whether
myricetin
could
inhibit
virusinduc
membran
fusion
process
shown
fig
moi
infect
vero
cell
obviou
syncytia
multinuclear
cell
observ
nontreat
viru
control
group
h
pi
howev
treatment
myricetin
h
pi
markedli
block
syncytium
format
limit
number
small
syncytia
suggest
myricetin
may
inhibit
hsvinduc
cell
fusion
addit
myricetin
treatment
h
pi
obvious
influenc
express
viru
surfac
glycoprotein
gd
protein
fig
thu
myricetin
may
directli
block
hsvinduc
membran
fusion
inhibit
function
viru
surfac
glycoprotein
rather
reduc
express
sinc
myricetin
inhibit
hsv
adsorpt
membran
fusion
question
whether
myricetin
directli
interact
viru
surfac
gd
protein
mainli
requir
hsv
entri
process
employ
drug
affin
respons
target
stabil
assay
dart
lomenick
et
al
reli
reduct
proteas
suscept
target
protein
upon
drug
bind
detect
potenti
interact
myricetin
gd
protein
brief
infect
vero
cell
lysat
digest
pronas
presenc
absenc
myricetin
amount
gd
protein
cell
lysat
detect
western
blot
shown
fig
gd
protein
obvious
protect
proteas
digest
extract
myricetin
treat
cell
especi
pronas
treatment
suggest
myricetin
may
interact
hsv
gd
protein
infect
vero
cell
howev
myricetin
could
protect
viru
surfac
glycoprotein
gb
gc
ghgl
protein
proteas
digest
infect
cell
fig
similarli
cellular
surfac
receptor
hvem
could
also
protect
proteas
digest
myricetin
fig
thu
myricetin
may
interfer
hsv
bind
entri
process
target
viru
gd
protein
rather
cellular
receptor
hsv
moreov
direct
interact
myricetin
gd
protein
evalu
use
spr
assay
geng
et
al
briefli
gd
protein
immobil
chip
myricetin
concentr
flow
biosensor
chip
surfac
respect
data
reveal
mark
bind
myricetin
viru
gd
protein
concentrationdepend
manner
kd
equival
nm
implic
high
affin
myricetin
gd
protein
fig
thu
pretreat
hsv
infect
moi
use
four
differ
treatment
condit
pre
viru
hsv
pretreat
myricetin
h
infect
ii
precel
vero
cell
pretreat
myricetin
infect
iii
adsorpt
vero
cell
infect
media
contain
myricetin
h
iv
postadsorpt
remov
unabsorb
viru
myricetin
ad
cell
h
pi
viru
yield
determin
plaqu
assay
result
present
mean
sd
five
independ
experi
p
vs
viru
control
group
b
vero
cell
infect
f
strain
four
treatment
condit
myricetin
express
viru
protein
detect
immunofluoresc
assay
scale
bar
repres
c
moi
infect
hela
cell
treat
without
myricetin
adsorpt
process
c
entri
process
wash
three
time
pb
immunofluoresc
assay
perform
use
antibodi
evalu
amount
virion
bind
enter
cell
scale
bar
repres
eg
averag
fluoresc
intens
protein
adsorpt
process
e
entri
process
f
measur
imagej
nih
version
usa
calcul
averag
intens
per
cell
differ
imag
n
averag
intens
cell
nucleu
entri
process
g
also
measur
imagej
usa
calcul
averag
intens
per
unit
area
cell
nucleu
differ
imag
n
averag
intens
nontreat
viru
control
cell
hsv
assign
valu
data
present
mean
sd
n
signific
p
vs
viru
control
group
hsv
w
li
et
al
antivir
research
myricetin
infect
may
allow
myricetin
fulli
bind
gd
protein
form
stabl
myricetingd
complex
furthermor
impact
myricetin
gd
bind
vero
cell
explor
use
cell
enzymelink
immunosorb
assay
previous
describ
tiwari
et
al
briefli
vero
cell
first
treat
without
myricetin
h
gd
protein
myricetin
pretreat
gd
protein
ad
cell
incub
anoth
h
gd
protein
firstli
immobil
onto
surfac
carboxymethyl
dextran
sensor
chip
assess
realtim
bind
myricetin
gd
protein
chip
myricetin
flow
biosensor
chip
surfac
sensorgram
bind
interact
record
real
time
analys
subtract
sensorgram
blank
channel
chang
mass
due
bind
respons
record
reson
unit
ru
f
gd
bind
assay
vero
cell
first
treat
without
myricetin
h
gd
protein
myricetin
pretreat
gd
protein
ad
cell
incub
anoth
h
respect
amount
gd
protein
bind
vero
cell
surfac
detect
elisa
assay
use
antigd
antibodi
hrp
label
secondari
antibodi
sequenti
valu
mean
sd
n
signific
p
vs
viru
control
group
g
h
g
h
bind
mode
myricetin
hsv
gd
protein
pdb
id
shown
myricetin
color
purpl
surround
residu
bind
pocket
color
cyan
backbon
receptor
depict
lightblu
cartoon
interpret
refer
color
figur
legend
reader
refer
web
version
articl
w
li
et
al
antivir
research
respect
amount
gd
protein
bind
vero
cell
surfac
detect
sequenti
incub
antigd
antibodi
hrp
label
secondari
antibodi
shown
fig
preincub
gd
protein
myricetin
significantli
reduc
bind
gd
cell
surfac
dosedepend
manner
howev
pretreat
cell
significantli
decreas
amount
gd
protein
cell
surfac
find
strongli
support
myricetin
may
interact
hsv
gd
protein
rather
cellular
receptor
block
viru
bind
entri
investig
bind
mode
myricetin
gd
dock
simul
studi
carri
use
crystal
structur
gd
protein
pdb
code
result
indic
oxygen
atom
carbanyl
group
myricetin
regard
hydrogen
bond
acceptor
form
two
hydrogen
bond
nitrogen
atom
amid
group
well
gd
fig
oxygen
atom
phenol
hydroxyl
group
myricetin
regard
hydrogen
bond
donor
form
hydrogen
bond
oxygen
atom
backbon
gd
oxygen
atom
hydroxyl
group
myricetin
regard
hydrogen
bond
donor
form
hydrogen
bond
oxygen
atom
carboxyl
group
gd
fig
h
thu
myricetin
may
interact
gd
hydrogen
bond
interact
sinc
myricetin
may
inhibit
hsv
entri
process
hela
cell
explor
whether
myricetin
could
influenc
hsv
infectionrel
signal
pathway
use
western
blot
assay
egfr
signal
pathway
report
requir
viru
endocytosi
replic
inhibitor
signal
could
inhibit
entri
fusion
hsv
eierhoff
et
al
tiwari
shukla
herein
treatment
myricetin
h
significantli
decreas
level
phosphoryl
egfr
normal
control
group
respect
p
fig
moreov
activ
downstream
signal
also
evalu
result
show
treatment
myricetin
h
significantli
decreas
level
phosphoryl
protein
normal
control
group
respect
p
fig
e
addit
treatment
myricetin
h
significantli
reduc
activ
akt
normal
control
group
respect
p
fig
f
howev
myricetin
treatment
significantli
influenc
total
express
level
egfr
akt
protein
infect
vero
cell
fig
h
thu
cellular
signal
pathway
may
involv
antihsv
fig
involv
signal
pathway
antihsv
action
myricetin
ac
moi
infect
cell
treat
without
myricetin
h
phosphoryl
egfr
b
akt
c
evalu
western
blot
blot
also
probe
gapdh
protein
load
control
result
shown
repres
three
separ
experi
df
quantif
immunoblot
ratio
pegfr
e
pakt
f
protein
gapdh
tubulin
respect
ratio
noninfect
cell
assign
valu
data
present
mean
sd
n
signific
p
vs
normal
control
group
mock
p
p
vs
viru
control
group
hsv
g
moi
infect
cell
treat
without
myricetin
h
total
express
level
egfr
akt
evalu
western
blot
result
shown
repres
three
separ
experi
h
quantif
immunoblot
ratio
egfr
akt
protein
respect
ratio
noninfect
cell
mock
assign
valu
data
present
mean
sd
n
w
li
et
al
antivir
research
action
myricetin
vitro
furthermor
myricetin
treatment
could
significantli
influenc
activ
egfr
akt
protein
noninfect
vero
cell
fig
b
suggest
inhibit
pathway
myricetin
may
relat
inhibit
hsv
infect
moreov
treatment
gd
protein
could
significantli
enhanc
phosphoryl
egfr
akt
protein
noninfect
vero
cell
p
suggest
activ
pathway
hsv
infect
cell
may
relat
bind
gd
cellular
receptor
fig
howev
myricetin
treatment
level
phosphoryl
egfr
akt
protein
significantli
reduc
compar
gd
treat
control
group
p
fig
addit
myricetin
treatment
also
significantli
reduc
express
level
gd
mrna
infect
vero
cell
p
fig
f
consid
pathway
requir
effici
hsv
replic
suppos
myricetin
may
abl
interact
viru
gd
protein
interfer
activ
pathway
inhibit
subsequ
replic
hsv
antihsv
effect
myricetin
test
murin
intranas
model
hsv
pneumonia
enceph
de
clercq
luczak
brief
f
strain
infect
mice
receiv
intraperiton
treatment
myricetin
acyclovir
placebo
pb
daili
five
day
shown
fig
intraperiton
treatment
myricetin
significantli
increas
surviv
rate
compar
placebotr
control
group
p
day
post
infect
individu
placebo
group
surviv
wherea
anim
myricetintr
group
surviv
superior
acyclovir
treat
group
moreov
bodi
weight
mice
viru
control
group
placebo
began
decreas
day
pi
lose
initi
weight
gradual
recov
howev
myricetin
treat
mice
gradual
increas
bodi
weight
limit
weight
loss
less
infect
superior
acyclovir
treat
group
fig
furthermor
four
day
postinfect
four
mice
treatment
group
sacrif
tissu
sampl
remov
analysi
subsequ
viral
titer
lung
spinal
cord
determin
plaqu
assay
quantit
rtpcr
result
show
treatment
myricetin
four
day
pulmonari
viru
titer
significantli
decreas
compar
viru
control
group
p
fig
rel
viru
gd
mrna
level
spinal
cord
also
significantli
reduc
compar
placebo
group
suggest
intraperiton
therapi
myricetin
could
inhibit
hsv
multipl
mice
fig
acyclovir
treatment
also
show
signific
reduct
viru
titer
mice
lung
spinal
cord
fig
evalu
effect
myricetin
viral
pneumonia
enceph
mice
histopatholog
analysi
also
perform
result
show
lung
tissu
viruscontrol
group
show
mark
infiltr
inflammatori
cell
presenc
massiv
hyperaemia
lumen
fig
howev
mice
treat
myricetin
follow
infect
intact
columnar
epithelium
even
presenc
tini
serocellular
exud
lumen
fig
inhibit
pathway
myricetin
may
relat
inhibit
gd
protein
noninfect
vero
cell
treat
without
myricetin
h
phosphoryl
egfr
akt
evalu
western
blot
blot
also
probe
protein
load
control
result
shown
repres
three
separ
experi
b
plot
quantifi
immunoblot
ratio
tubulin
pegfr
pakt
protein
ratio
nontreat
cell
mock
assign
valu
data
present
mean
sd
n
c
vero
cell
treat
without
gd
protein
presen
absenc
myricetin
h
phosphoryl
egfr
akt
evalu
western
blot
blot
also
probe
gapdh
protein
load
control
result
shown
repres
three
separ
experi
quantif
immunoblot
ratio
pegfr
pakt
protein
gapdh
respect
ratio
nontreat
control
cell
mock
assign
valu
data
present
mean
sd
n
signific
p
vs
normal
control
group
mock
p
p
vs
gd
treat
control
group
gd
e
f
hsv
moi
infect
vero
cell
treat
myricetin
incub
h
total
rna
extract
realtim
rtpcr
assay
e
f
gd
mrna
cellular
mrna
rel
amount
hsv
gd
mrna
determin
use
compar
method
rna
level
nontreat
viru
control
cell
hsv
assign
valu
valu
mean
sd
n
signific
p
p
vs
viru
control
group
w
li
et
al
antivir
research
fig
antihsv
action
myricetin
vivo
surviv
rate
infect
mice
receiv
intraperiton
treatment
myricetin
acyclovir
placebo
pb
daili
five
day
result
express
percentag
surviv
evalu
daili
day
signific
p
p
vs
viru
control
group
placebo
b
hsv
infect
mice
receiv
intraperiton
treatment
indic
compound
five
day
averag
bodi
weight
group
monitor
daili
day
express
percentag
initi
valu
c
viral
titer
lung
spinal
cord
intraperiton
therapi
indic
compound
five
day
viral
titer
lung
c
spinal
cord
evalu
plaqu
assay
quantit
rtpcr
assay
day
pi
respect
valu
mean
sd
n
signific
p
p
vs
viru
control
group
e
f
histopatholog
analys
lung
brain
tissu
day
pi
stain
repres
micrograph
group
shown
mock
noninfect
mice
tissu
infect
tissu
without
drug
infect
tissu
acyclovir
treatment
infect
tissu
myricetin
treatment
infect
tissu
myricetin
treatment
black
arrow
indic
presenc
hyperaemia
infiltr
inflammatori
cell
lumen
fig
addit
treatment
myricetin
nearli
hyperaemia
infiltr
inflammatori
cell
brain
tissu
fig
myricetin
treat
mice
tini
hyperaemia
brain
tissu
compar
effect
acyclovir
fig
thu
myricetin
may
abl
attenu
pneumonia
enceph
symptom
hsv
infect
mice
myricetin
member
flavonoid
class
polyphenol
compound
report
possess
antivir
activ
lot
virus
includ
hiv
sarscov
ong
khoo
studi
discov
myricetin
possess
activ
differ
cell
low
toxic
si
myricetin
may
block
hsv
infect
direct
interact
viru
gd
protein
interfer
viru
adsorpt
membran
fusion
differ
nucleosid
analogu
acyclovir
importantli
intraperiton
therapi
mice
myricetin
markedli
improv
surviv
reduc
viru
titer
lung
spinal
cord
pretreat
hsv
myricetin
infect
significantli
reduc
viru
titer
hsv
infect
cell
suggest
myricetin
may
direct
interact
hsv
particl
addit
myricetin
block
hsv
induc
membran
fusion
interfer
viru
bind
entri
process
suggest
myricetin
may
interact
surfac
glycoprotein
hsv
result
dart
assay
gd
bind
assay
indic
myricetin
may
interact
viru
gd
protein
rather
cellular
receptor
hsv
block
viru
bind
entri
fig
data
spr
assay
verifi
myricetin
truli
bind
gd
protein
high
affin
kd
nm
fig
molecular
dock
analysi
indic
myricetin
may
interact
gd
protein
hydrogen
bond
interact
fig
h
furthermor
myricetin
treatment
inhibit
activ
egfr
akt
protein
hsv
infect
gd
treat
noninfect
cell
reduc
mrna
level
viru
protein
hsvinfect
cell
fig
consid
pathway
requir
effici
hsv
replic
tiwari
shukla
suppos
myricetin
may
interact
viru
gd
protein
interfer
activ
pathway
inhibit
subsequ
replic
hsv
mous
model
hsv
intranas
infect
use
studi
hsv
induc
pneumonia
enceph
gamba
et
al
studi
intraperiton
therapi
mice
myricetin
markedli
improv
surviv
inhibit
hsv
multipl
lung
spinal
cord
fig
moreov
histopatholog
analysi
indic
myricetin
treatment
also
significantli
attenu
pneumonia
enceph
symptom
hsvinfect
mice
compar
effect
acyclovir
contrast
acyclovir
myricetin
block
hsv
bind
entri
process
low
toxic
suggest
may
use
therapi
prophylaxi
hsv
infect
howev
oral
administr
myricetin
antivir
may
unlik
success
rapid
metabol
thu
myricetin
may
use
prevent
treatment
herp
simplex
pneumonia
enceph
intraven
administr
futur
summari
myricetin
possess
antihsv
activ
vitro
vivo
low
toxic
myricetin
may
block
hsv
infect
direct
interact
viru
gd
protein
interf
viru
adsorpt
membran
fusion
addit
cellular
egfr
pathway
also
involv
antihsv
action
myricetin
thu
myricetin
merit
investig
novel
antihsv
agent
target
viru
gd
protein
host
pathway
studi
antihsv
effect
myricetin
clinic
strain
especi
acyclovirresist
strain
requir
advanc
drug
develop
nevertheless
myricetin
potenti
develop
novel
antivir
inject
therapi
herp
simplex
enceph
pneumonia
futur
none
declar
